600285 羚锐制药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)6.98923.46624.64521.27019.268
总资产报酬率 ROA (%)4.24714.26014.76312.46311.436
投入资产回报率 ROIC (%)6.17321.15022.82319.20417.403

边际利润分析
销售毛利率 (%)78.18880.02975.81873.29372.280
营业利润率 (%)25.33223.02623.14619.81917.227
息税前利润/营业总收入 (%)24.81322.69123.10018.66016.338
净利润/营业总收入 (%)21.97419.78620.64017.15615.501

收益指标分析
经营活动净收益/利润总额(%)97.22193.66188.53496.19180.738
价值变动净收益/利润总额(%)4.1544.8524.8583.10512.491
营业外收支净额/利润总额(%)0.090-0.8882.087-0.500-0.017

偿债能力分析
流动比率 (X)1.1711.0781.3111.3681.465
速动比率 (X)0.9920.8711.0791.1221.181
资产负债率 (%)38.22539.03138.60141.35141.114
带息债务/全部投入资本 (%)7.69011.3673.5667.0437.415
股东权益/带息债务 (%)1,171.840760.9632,650.2781,286.2061,213.334
股东权益/负债合计 (%)160.013154.601158.660141.446142.802
利息保障倍数 (X)-45.782-171.772-42.821-17.595-18.446

营运能力分析
应收账款周转天数 (天)39.21935.02329.70724.69822.119
存货周转天数 (天)151.926203.872191.857194.120197.887